Loading
A phase 2 trial of Pembrolizumab, Doxorubicin, Vinblastine in hodgkin lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) is a phase 2 interventional study registered as NCT03407144 by Merck Sharp & Dohme LLC, with 340 participants planned, started 2018-04-09 and due to reach its primary completion in 2026-11-06. Interventions recorded: pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide. Conditions listed: Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II), Doxorubicin.
Shares Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II), Doxorubicin.
Shares Dacarbazine, Vincristine, Doxorubicin, Cyclophosphamide.
Shares Dacarbazine, Vinblastine, Doxorubicin, Hodgkin lymphoma.
Shares Dacarbazine, Vinblastine, Doxorubicin, Hodgkin lymphoma.
Shares Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II), Vincristine.
Shares Vincristine, Doxorubicin, Cyclophosphamide, Hodgkin lymphoma.
Shares Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II), Vincristine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/